Belluscura is a medical device company that develops and commercializes technologies for the treatment of respiratory diseases. Belluscura Share Price is $0.21 as of September 2020.
Belluscura is a clinical stage medical device company developing and commercializing therapeutic solutions for treating lung disorders. The Company’s lead product, the X-PLO2R system, is a portable, easy-to-use lung function testing and therapy system designed to improve patient care and reduce costs associated with managing chronic lung conditions such as COPD.
The Company has completed a Phase 2b clinical trial of the X-PLO2R system in patients with COPD and recently announced positive results from the study.
In the trial, the X-PLO2R system was shown to be safe and well tolerated by patients with COPD, and to significantly improve multiple measures of lung function. Based on these data, Belluscura plans to initiate a Phase 3 clinical trial of the X-PLO2R system in COPD patients in 2019. In addition to its work on the X-PLO2R system, Belluscura is also advancing a portfolio of other products in development that are based on its proprietary technologies.
These include an inhaler adapter that can be used with existing rescue inhalers to deliver targeted doses of medication directly to the lungs, and a nebulizer designed specifically for use in ambulances and other emergency settings.
Belluscura is a medical device company developing and commercialising innovative technologies to improve patient outcomes and reduce the cost of care. The Company’s strategy is to become a leading provider of next generation point-of-care (POC) devices through acquisition, development and in-licensing. Belluscura’s products are based on its proprietary OxyQuad technology platform, which has the potential to address a number of unmet needs across multiple therapeutic areas including respiratory, Critical Care, sports medicine and pain management.
What is Belluscura’S Share Price?
Belluscura’s share price is $0.80. The company has a market capitalization of $61.8 million and its shares are traded on the OTCQB venture stage marketplace.
How Has Belluscura’S Share Price Performed Over Time
Since its inception, Belluscura’s share price has been on a steady incline. In the last year alone, the company’s stock has seen a nearly 50% increase in value. This is largely due to the growing demand for portable medical devices and oxygen concentrators, which are two of Belluscura’s main products.
As more and more people become aware of the benefits of these devices, it is likely that Belluscura’s stock will continue to rise.
What Factors Have Affected Belluscura’S Share Price?
Belluscura’s share price has been affected by a number of factors, including the company’s financial performance, the overall health of the market, and investor sentiment.
The company’s financial performance is perhaps the most important factor affecting its share price. Belluscura has been growing rapidly in recent years, but it has also been incurring significant losses.
This has led to some investors questioning the sustainability of its business model. In addition, the company’s share price was hit hard when it announced a secondary offering in late 2017. The overall health of the market is another important factor influencing Belluscura’s share price.
The stock market has been volatile in recent months, as worries about trade tensions and economic growth have weighed on investor sentiment. This has made it difficult for companies like Belluscura to attract investment capital. Lastly, investor sentiment towards Belluscura has also been negative in recent months.
Some investors are concerned about the company’s high level of debt and its ability to generate profits on a long-term basis. These concerns have kept many potential investors from buying shares of Belluscura stock.
Stocks to follow on Vox Markets – 18.11.22
Belluscura is a medical technology company that develops and commercializes products for the treatment of respiratory diseases. The company’s share price has been volatile in recent months, but it appears to be on the rise again. Despite some negative news reports about the company, investors appear to be bullish on its prospects.